2. Neurological Disease

Neurological Disease

Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162061
    ChEs/MAOs-IN-1
    ChEs/MAOs-IN-1 (Compound 4i) is a dual inhibitor of cholinesterases (ChEs) and monoamine oxidases (MAOs).ChEs/MAOs-IN-1 has IC50 values of 0.048 μM, 0.89 μM, 3.58 μM, and 0.095 μM for AChE, BChE, MAO-B and MAO-B respectively. ChEs/MAOs-IN-1 can be used in the study of neurodegenerative diseases.
    ChEs/MAOs-IN-1
  • HY-162083
    CB2R/5-HT1AR agonist 1 2821085-76-9
    CB2R/5-HT1AR agonist 1 (Compound 2o) is an orally active partial agonist of the CB2 receptor (EC50=479.6 nM). CB2R/5-HT1AR agonist 1 is a full agonist of 5-HT1A receptor (EC50=2.7 μM). CB2R/5-HT1AR agonist 1 exhibits anti-anxiety and anti-depressive effects. CB2R/5-HT1AR agonist 1 possesses favorable pharmacokinetic properties.
    CB2R/5-HT1AR agonist 1
  • HY-162093
    Aβ1–42 aggregation inhibitor 2 3036099-60-9
    Aβ1–42 aggregation inhibitor 2 (compound 7c) is a potent inhibitor of Aβ1-42 aggregation that plays an important role in Alzheimer's disease research. Aβ1–42 aggregation inhibitor 2 displays excellent antioxidant, metal ions chelating, oxidative stress alleviation, neuroprotective and anti-neuroinflammatory activities.
    Aβ1–42 aggregation inhibitor 2
  • HY-162117
    LBG30300
    LBG30300 is a subtype-selective mGlu2 receptor agonist EC50 0.6 nM. LBG30300 is blood-brain barrier permeable.
    LBG30300
  • HY-162118
    RGH-122 2355304-05-9
    RGH-122 (compound 43) is an orally active, potent, selective, and hV1a receptor antagonist with Ki value of 0.3 nM and IC50 of 0.9 nM. RGH-122 showes microsomal stability with CLint value of 13/28/25 μL/min/mg.
    RGH-122
  • HY-162127
    hAChE/hBACE-1-IN-3
    hAChE/hBACE-1-IN-3 (Compound 23a) is a mixed-type inhibitor of hAChE and hBACE-1 with IC50 values of 0.32 μM and 0.39 μM, respectively, Ki values of 0.26 μM and 0.46 μM, respectively. hAChE/hBACE-1-IN-3 can penetrate the blood-brain barrier.
    hAChE/hBACE-1-IN-3
  • HY-162138
    BChE-IN-23 2020357-32-6
    BChE-IN-23 (compound 2a) is a BChE inhibitor with an IC50 value of 21 nM. BChE-IN-23 can be used in Alzheimer's disease (AD) research.
    BChE-IN-23
  • HY-162162
    RXR agonist 1
    RXR agonist 1 (Compound 33) is a highly selective RXR agonist, with EC50s of 9 nM, 18 nM, and 11 nM for RXRα, RXRβ, and RXRγ, respectively. RXR agonist 1 binds to RXR with high affinity (Kd = 0.03 μM).
    RXR agonist 1
  • HY-162164
    Neuroprotective agent 3 130995-63-0
    Neuroprotective agent 3 (Compound 21a) is an antioxidant that exhibits neuroprotective effects. Neuroprotective agent 3 significantly increases neuronal viability and induces neuroprotection, as well as improves neurological deficit scores in an in vivo model of transient cerebral ischemia.
    Neuroprotective agent 3
  • HY-162165
    Neuroprotective agent 4 161095-11-0
    Neuroprotective agent 4 (compound 24a) is a novel and effective small molecule antioxidant. Neuroprotective agent 4 has a neuroprotective effect. Neuroprotective agent 4 can be used in the study of ischemic stroke and related diseases.
    Neuroprotective agent 4
  • HY-162167
    COX-1-IN-1 1369503-03-6
    COX-1-IN-1 (compound 15a) is a selective inhibitor for cyclooxygenase (COX), with IC50s of 0.23 μM (COX-1) and >50 μM (COX-2), selective index (COX-2 IC50/COX-1 IC50) is 217. COX-1-IN-1 inhibits platelet aggregation.
    COX-1-IN-1
  • HY-162232
    mGluR2 agonist 1
    mGluR2 agonist 1 (Compound 5b) is a potent and selective metabotropic glutamate 2 receptor (mGluR) agonist with an EC50 of 82 nM. mGluR2 agonist 1 can be used for the research of central nervous system (CNS) diseases.
    mGluR2 agonist 1
  • HY-162246
    Nav1.8-IN-5 3023247-79-9
    Nav1.8-IN-5 (Example 1) is a voltage-gated sodium channel Nav1.8 inhibitor. Nav1.8-IN-5 can be used for Nav1.8-mediated diseases, such as pain and pain-related disorders, as well as cardiovascular diseases (such as atrial fibrillation) research.
    Nav1.8-IN-5
  • HY-162258
    AChE-IN-57
    AChE-IN-57 (compound 5b(SP-2)) is a potent AChE inhibitor. AChE-IN-57 improves cognitive defects. AChE-IN-57 restores the biochemical mediators and inhibits reactive oxygen and nitrogen species implicated in the neuroinflammation mechanism. AChE-IN-57 has the potential for the research of Alzheimer.
    AChE-IN-57
  • HY-162269
    Nampt activator-5
    Nampt activator-5 (compound C8) is a potent nicotinamide phosphoribosyltransferase (NAMPT) activator with a KD value of 6.19 µM. Nampt activator-5 shows a cellular antisenescence effect. Nampt activator-5 promotes the production of NAD+ in the brain and reduces the expression of age-related markers and secretory phenotypes. Nampt activator-5 has the potential for the research of age-related diseases.
    Nampt activator-5
  • HY-162277
    BuChE-IN-10
    BuChE-IN-10 (compound 7p) is an inhibitor of BuChE (eqBuChE IC50 = 4.68 nM, huBuChE IC50 = 9.12 nM). BuChE-IN-10 has anti-neuroinflammatory activity and exhibits high BBB permeability.
    BuChE-IN-10
  • HY-162303
    C175-0062 686736-69-6
    C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS).
    C175-0062
  • HY-162304
    MAGL-IN-14 2770967-04-7
    MAGL-IN-14 (compound 2) is a potent inhibitor of MAGL, with IC50 of 0.00289 μM and 0.002 μM in HEK293 and PC3 cells, respectively.
    MAGL-IN-14
  • HY-162305
    MAGL-IN-15 2770967-08-1
    MAGL-IN-15 (Compound 6) is a MAGL inhibitor that can be used in the research of diseases and disorders related to the regulation of endocannabinoid system signaling activities.
    MAGL-IN-15
  • HY-162315
    MAGL-IN-16
    MAGL-IN-16 (compound 27) is an oral active, selective and reversible MAGL inhibitor with the IC50 value of 10.3 nM. MAGL-IN-16 can increase the level of 2-AG and shows antidepressant effect in mouse depressed model caused by chronic restraint stress.
    MAGL-IN-16
Cat. No. Product Name / Synonyms Application Reactivity
  •  
  •